{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:23:39Z","timestamp":1761855819850,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":1415,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1136\/esmoopen-2016-000101","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T20:10:13Z","timestamp":1492114213000},"page":"e000101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy"],"prefix":"10.1016","volume":"2","author":[{"given":"Saoirse O.","family":"Dolly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Migali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Della-Pepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelize","family":"Khakoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Hazell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2016-000101_bb0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","article-title":"Diffuse malignant peritoneal mesothelioma-an update on treatment","volume":"38","author":"Mirarabshahii","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/esmoopen-2016-000101_bb0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.14694\/EdBook_AM.2013.33.182","article-title":"Peritoneal mesothelioma: the site of origin matters","author":"Kindler","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1136\/esmoopen-2016-000101_bb0020","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/bjs.5377","article-title":"Sex difference in diffuse malignant peritoneal mesothelioma","volume":"93","author":"Yan","year":"2006","journal-title":"Br J Surg"},{"key":"10.1136\/esmoopen-2016-000101_bb0025","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/annonc\/mdl345","article-title":"Epidemiology of peritoneal mesothelioma: a review","volume":"18","author":"Boffetta","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0030","first-page":"59","article-title":"Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management","volume":"52","author":"Chua","year":"2009","journal-title":"Can J Surg"},{"key":"10.1136\/esmoopen-2016-000101_bb0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J Cell Physiol"},{"key":"10.1136\/esmoopen-2016-000101_bb0040","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1136\/esmoopen-2016-000101_bb0045","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5858\/2005-129-403-MDMADC","article-title":"Malignant deciduoid mesothelioma: a diagnostic challenge","volume":"129","author":"Mourra","year":"2005","journal-title":"Arch Pathol Lab Med"},{"key":"10.1136\/esmoopen-2016-000101_bb0050","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2012.105","article-title":"Deciduoid mesothelioma: report of 21 cases with review of the literature","volume":"25","author":"Ord\u00f3\u00f1ez","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1136\/esmoopen-2016-000101_bb0055","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00000478-200404000-00013","article-title":"Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases","volume":"28","author":"Galateau-Sall\u00e9","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/esmoopen-2016-000101_bb0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4240\/wjgs.v1.i1.38","article-title":"Malignant peritoneal mesothelioma","volume":"1","author":"Munkholm-Larsen","year":"2009","journal-title":"World J Gastrointest Surg"},{"key":"10.1136\/esmoopen-2016-000101_bb0065","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.ejso.2008.09.010","article-title":"Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma","volume":"35","author":"Yano","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1245\/ASO.2006.03.045","article-title":"Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion","volume":"13","author":"Deraco","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0075","first-page":"51","article-title":"New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials","volume":"7","author":"Kotova","year":"2015","journal-title":"Cancer Manag Res"},{"key":"10.1136\/esmoopen-2016-000101_bb0080","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"10.1136\/esmoopen-2016-000101_bb0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1136\/esmoopen-2016-000101_bb0095","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","article-title":"Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial","volume":"26","author":"Simon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0100","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0105","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and leukemia group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2016-000101_bb0110","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLC.2006.n.003","article-title":"Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid","volume":"7","author":"Krug","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1136\/esmoopen-2016-000101_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0125","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.7083","article-title":"SWOG 0722: a phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM)","volume":"30","author":"Garland","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0130","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejcts.2007.09.045","article-title":"PTEN expression is a strong predictor of survival in mesothelioma patients","volume":"33","author":"Opitz","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1136\/esmoopen-2016-000101_bb0135","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s13277-012-0615-9","article-title":"PTEN protein expression in malignant pleural mesothelioma","volume":"34","author":"Agarwal","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1136\/esmoopen-2016-000101_bb0140","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-11-2259","article-title":"Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma","volume":"18","author":"Carbone","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2016-000101_bb0145","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1136\/esmoopen-2016-000101_bb0150","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2016-000101_bb0155","first-page":"s2","article-title":"Evaluation of tolerability and antitumour activity of GDC-0980, an oral PI3K\/MTOR inhibitor, administered to patients with advanced malignant pleural mesothelioma (MPM)","volume":"8","author":"Dolly","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0160","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0165","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1136\/esmoopen-2016-000101_bb0170","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1136\/esmoopen-2016-000101_bb0175","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1245\/s10434-006-9192-8","article-title":"Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion","volume":"14","author":"Baratti","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/esmoopen-2016-000101_bb0180","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1078-0432.CCR-07-1613","article-title":"Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC\/mesothelin increases its potential as a useful serum tumor marker for mesothelioma","volume":"14","author":"Shiomi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2016-000101_bb0185","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1136\/esmoopen-2016-000101_bb0190","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920324674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920324674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2016-000101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:19:28Z","timestamp":1761855568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920324674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"alternative-id":["S2059702920324674"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2016-000101","relation":{},"ISSN":["2059-7029"],"issn-type":[{"type":"print","value":"2059-7029"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2016-000101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000101"}}